

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

H. G. Bone^{1,10} · D. W. Dempster² · J. A. Eisman³ · S. L. Greenspan⁴ · M. R. McClung⁵ ·
T. Nakamura⁶ · S. Papapoulos⁷ · W. J. Shih⁸ · A. Rybak-Feiglin⁹ · A. C. Santora⁹ ·
N. Verbruggen⁹ · A. T. Leung⁹ · A. Lombardi⁹

Published online: 10 September 2015

© International Osteoporosis Foundation and National Osteoporosis Foundation 2015

Erratum to: Osteoporos Int
DOI:10.1007/s00198-014-2944-6

Owing to an oversight, an incorrect supplementary file was published with this article. The correct electronic supplementary material is supplied with the online version of this erratum. The publisher apologizes for this error and for any inconvenience caused.

Electronic supplementary material The online version of this article (doi:10.1007/s00198-015-3274-z) contains supplementary material, which is available to authorized users.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00198-014-2944-6>.

✉ H. G. Bone
hgbone.md@att.net

¹ Michigan Bone & Mineral Clinic, Detroit, MI, USA

² Columbia University, New York, NY, USA

³ Garvan Institute of Medical Research, University of Notre Dame Australia, St Vincent's Hospital and UNSW Australia, Sydney, Australia

⁴ University of Pittsburgh, Pittsburgh, PA, USA

⁵ Oregon Osteoporosis Center, Portland, OR, USA

⁶ University of Occupational and Environmental Health, Kitakyushu, Japan

⁷ Leiden University Medical Center, Leiden, Netherlands

⁸ Robert Wood Johnson Medical School, Piscataway, NJ, USA

⁹ Merck Sharp and Dohme Corp., Whitehouse Station, NJ, USA

¹⁰ The Osteoporosis Center at St. Luke's Hospital, Chesterfield, MO, USA